Non-Communicable Diseases — MCQs

Q: What is the post-exposure rabies vaccination schedule for a patient who has already been immunized?

0, 3. **Explanation:** The correct answer is **A (0, 3)**. This follows the WHO and National Guidelines for Rabies Prophylaxis regarding **re-exposure** in previously immunized individuals. **1. Why Option A is Correct:** When a person has documented evidence of a complete pre-exposure or post-exposure vaccination course (using modern Cell Culture Vaccines), they possess "immunological memory." Upon re-exposure, a rapid "booster" effect is required to elevate antibody titers. The recommended schedule is **two doses** of the vaccine, administered intramuscularly (or intradermally) on **Days 0 and 3**. Crucially, Rabies Immunoglobulin (RIG) is **not** required for these patients, even for Category III bites. **2. Why Other Options are Incorrect:** * **Option B (0, 3, 14):** This is not a standard recognized schedule for rabies. * **Option C (0, 7, 28):** This is the standard **Pre-exposure Prophylaxis (PrEP)** schedule for high-risk individuals (e.g., veterinarians, lab workers). * **Option D (8, 4, 0, 1, 1):** This refers to the **Thai Red Cross (Intradermal) Schedule** (2-2-2-0-2), but the numbers provided are jumbled and do not represent a standard post-exposure regimen. **High-Yield Clinical Pearls for NEET-PG:** * **Definition of "Previously Immunized":** A person who has received a full course of PEP or PrEP with Cell Culture Vaccine (CCV) or Purified Duck Embryo Vaccine (PDEV). * **RIG Rule:** RIG is contraindicated in previously immunized individuals as it may interfere with the secondary immune response. * **Standard PEP (Unvaccinated):** The Essen schedule (IM) is **0, 3, 7, 14, 28**. * **Site of Injection:** Always the **deltoid** in adults and the **anterolateral thigh** in children. **Never** in the gluteal region (due to lower neutralizing antibody titers).

Q: Which disease requires a vaccination certificate for international travel?

Yellow fever. **Explanation:** The correct answer is **Yellow Fever**. Under the **International Health Regulations (IHR 2005)**, Yellow Fever is currently the only disease for which an International Certificate of Vaccination or Prophylaxis (ICVP) is legally required for travel between endemic and non-endemic zones. **Why Yellow Fever is correct:** Yellow Fever is a viral hemorrhagic fever transmitted by the *Aedes aegypti* mosquito. To prevent the "re-introduction" of the virus into countries where the vector is present but the disease is not (like India), travelers arriving from endemic zones (Sub-Saharan Africa and South America) must provide a valid vaccination certificate. The vaccine used is the **17D strain**, and the certificate becomes valid **10 days** after vaccination, lasting for the **lifetime** of the individual. **Why the other options are incorrect:** * **Cholera:** While previously required, the WHO removed Cholera from the list of mandatory vaccinations for international travel because the parenteral vaccine provides poor protection and does not prevent asymptomatic carriage. * **Hepatitis & Tetanus:** These are recommended vaccinations for personal protection based on the traveler's destination and risk profile, but they are not legally mandated by international law for border crossing. **High-Yield Clinical Pearls for NEET-PG:** * **Validity:** A Yellow Fever certificate is valid for life (as per 2016 WHO amendment). * **Quarantine:** If a traveler from an endemic zone lacks a valid certificate, they are kept in a mosquito-proof isolation ward for **6 days** (the incubation period of the disease). * **Polio:** Note that some countries (including India) may require Polio vaccination (OPV/IPV) for travelers coming from specific polio-endemic countries, but Yellow Fever remains the primary global requirement under IHR.

Q: All of the following are modes of transmission of leprosy except?

Blood transfusion. **Explanation:** Leprosy, caused by *Mycobacterium leprae*, is primarily a chronic infectious disease of the skin and peripheral nerves. Understanding its transmission is crucial for NEET-PG. **Why Blood Transfusion is the Correct Answer:** Unlike many other bacterial infections, **blood transfusion** is not a recognized mode of transmission for leprosy. *M. leprae* is an obligate intracellular pathogen that resides primarily within macrophages and Schwann cells. It does not survive well or circulate in the free plasma in concentrations sufficient to cause infection via transfusion. **Analysis of Incorrect Options:** * **Droplet Infection (Option D):** This is the **most common** and primary route of transmission. Bacilli are shed in large numbers from the nasal mucosa of untreated lepromatous patients and enter the susceptible host through the upper respiratory tract. * **Transplacental Spread (Option C):** Vertical transmission from an infected mother to the fetus across the placenta has been documented, though it is relatively rare. * **Breast Milk (Option A):** *M. leprae* has been detected in the breast milk of lactating mothers with lepromatous leprosy, making it a possible, albeit less common, route of transmission. **High-Yield Clinical Pearls for NEET-PG:** * **Incubation Period:** Average 3–5 years (the longest among bacterial infections). * **Portal of Entry:** Respiratory tract (most common) and broken skin. * **Infectivity:** Patients become non-infectious within days of starting Multidrug Therapy (MDT). * **Classification:** Ridley-Jopling (Immunological) vs. WHO (Operational: Paucibacillary vs. Multibacillary). * **First Sign:** Usually a pale (hypopigmented) or reddish patch on the skin with loss of sensation.

Q: Which indicator best represents the vector's burden in human malaria transmission?

Man biting rate. ### Explanation **Correct Option: A. Man biting rate** The **Man Biting Rate (MBR)** is the most direct measure of the **vector's burden** in the transmission cycle. It is defined as the average number of bites received by a single person from a specific vector species per unit of time (usually per day). Since malaria transmission depends entirely on the frequency of contact between the mosquito and the human host, MBR is the primary indicator of the intensity of the vector's activity and the risk of exposure. **Analysis of Incorrect Options:** * **B. Inoculation Rate:** This measures the number of **infective** bites per person per unit of time. While it indicates transmission risk, it is a subset of the biting rate (only counting mosquitoes with sporozoites) and represents the "force of infection" rather than the overall vector burden. * **C. Slide Positive Rate (SPR):** This is a **parasitological indicator** derived from human surveillance (number of positive slides per 100 slides examined). It reflects the prevalence of the disease in the human population, not the vector's burden. * **D. Human Blood Index (HBI):** This measures the proportion of blood meals taken by a mosquito population from human hosts versus animals. It indicates the **host preference (anthropophily)** of the vector but does not quantify the frequency of biting or the total burden. **High-Yield Pearls for NEET-PG:** * **Annual Parasite Incidence (API):** The most sensitive index for measuring malaria burden in a community (used for planning under NCVBDC). * **Annual Blood Examination Rate (ABER):** Measures the efficiency of the surveillance system (Target: >10%). * **Entomological Inoculation Rate (EIR):** The best measure of the "force of infection" in an area (MBR × Sporozoite Rate). * **Infant Parasite Rate:** The best indicator of **recent/ongoing transmission** in a locality.

Q: Under the National Programme for Control of Blindness, what is the target goal for the prevalence of blindness?

0.31%. The **National Programme for Control of Blindness and Visual Impairment (NPCBVI)**, launched in 1976, is a high-yield topic for NEET-PG. The primary objective of the programme is to reduce the prevalence of blindness through systematic intervention. ### **Explanation of the Correct Answer** **Option B (0.31%)** is correct. According to the **National Blindness and Visual Impairment Survey (2015-2019)**, the prevalence of blindness in India was found to be **0.36%**. Following these findings, the revised target goal under the NPCBVI was set to reduce the prevalence of blindness to **0.3% (specifically 0.31%) by the year 2020**. This target aligns with the global "VISION 2020: The Right to Sight" initiative. ### **Analysis of Incorrect Options** * **Option A (0.10%):** This is an over-ambitious figure and does not correspond to any current national or global target for total blindness prevalence. * **Option C (0.50%):** This was the previous target goal of the NPCB. However, once the prevalence dropped below this level (as per the 2015-19 survey), the target was further lowered to 0.31%. * **Option D (1%):** This represents the historical prevalence of blindness in India during the early phases of the programme (it was 1.1% in 2001-02). ### **High-Yield Clinical Pearls for NEET-PG** * **Definition of Blindness (NPCBVI):** Visual acuity < 3/60 in the better eye with best possible correction. * **Most Common Cause of Blindness in India:** Cataract (approx. 66.2%). * **Most Common Cause of Visual Impairment:** Uncorrected Refractive Errors. * **Target Population:** The programme focuses heavily on the 50+ age group, where the prevalence is significantly higher (approx. 1.99%). * **WHO Definition Change:** Note that the NPCBVI definition of blindness was recently updated to align with the WHO definition (changing from < 6/60 to < 3/60) to ensure uniform global reporting.

Q: Which of the following is most strongly associated with coronary heart disease?

Apolipoproteins. **Explanation:** The correct answer is **Apolipoproteins**. In modern cardiovascular epidemiology, apolipoproteins (specifically the **ApoB/ApoA1 ratio**) are considered the most accurate and strongest predictors of coronary heart disease (CHD) risk, even superior to traditional lipid profiles. 1. **Why Apolipoproteins are correct:** Apolipoproteins are the protein components of lipoproteins. **ApoB** is found on all atherogenic particles (LDL, VLDL, IDL), representing the total number of potentially harmful particles. **ApoA1** is the primary protein of HDL (cardioprotective). The INTERHEART study established that the ApoB/ApoA1 ratio is a more powerful predictor of myocardial infarction than any other lipid parameter because it reflects the balance between cholesterol transport into the arterial wall versus its removal. 2. **Why other options are incorrect:** * **VLDL:** While VLDL contributes to triglyceride transport, it is a less specific predictor of CHD compared to the total atherogenic burden measured by ApoB. * **HDL:** Often called "good cholesterol," a low HDL is a risk factor, but it is a less potent predictor of clinical events than the ratio of atherogenic to anti-atherogenic particles. * **Total Lipoproteins:** This is a broad category. Total cholesterol levels can be misleading if a patient has high HDL, making it a weaker predictor than specific apolipoprotein markers. **High-Yield Clinical Pearls for NEET-PG:** * **INTERHEART Study:** Identified the ApoB/ApoA1 ratio as the single most important risk factor for MI globally. * **Rule of Thumb:** High ApoB = High Risk; High ApoA1 = Low Risk. * **Metabolic Syndrome:** Characterized by high triglycerides and low HDL, but even here, ApoB remains a more stable marker as it is not affected by fasting status.

Q: In sickle cell trait patients, there is a reduced risk of which of the following diseases?

Malaria. **Explanation:** The correct answer is **Malaria**. This phenomenon is a classic example of **Heterozygote Advantage** (or Balanced Polymorphism), where the sickle cell trait (HbAS) provides a survival advantage against severe malaria, specifically *Plasmodium falciparum*. **Why Malaria is the correct answer:** Individuals with sickle cell trait have red blood cells (RBCs) that tend to sickle when infected by the parasite. These damaged RBCs are prematurely cleared by the spleen, reducing the overall parasite load. Furthermore, the sickling process disrupts the parasite's ability to digest hemoglobin and impairs the expression of adhesion proteins (like PfEMP-1) on the RBC surface, preventing the sequestration of infected cells in vital organs. This significantly reduces the risk of severe complications like cerebral malaria. **Analysis of Incorrect Options:** * **A. Typhoid:** Caused by *Salmonella typhi*, this is a bacterial infection of the gastrointestinal tract and bloodstream. Hemoglobinopathies do not provide protective immunity against it. * **C. G-6PD deficiency:** This is a separate genetic enzymopathy. While both G-6PD deficiency and Sickle Cell Trait are prevalent in malaria-endemic regions due to similar evolutionary pressures, one does not reduce the risk of the other. * **D. Filaria:** This is a helminthic infection involving the lymphatic system. Its pathogenesis is unrelated to hemoglobin structure or RBC survival. **High-Yield Clinical Pearls for NEET-PG:** * **Balanced Polymorphism:** This term describes how a potentially harmful allele (HbS) is maintained in a population because the heterozygote state (HbAS) offers a survival benefit. * **Other Protective Traits:** Besides Sickle Cell Trait, **G-6PD deficiency**, **Thalassemia**, and **Duffy Antigen negativity** (protective against *P. vivax*) are also associated with malaria resistance. * **Diagnosis:** On Hb electrophoresis, Sickle Cell Trait shows **HbA > HbS**.

Q: Which species of Anopheles mosquito is responsible for urban malaria?

Anopheles stephensi. **Explanation:** The correct answer is **Anopheles stephensi**. In India, malaria transmission is highly dependent on the specific ecological niches of various *Anopheles* species. **1. Why Anopheles stephensi is correct:** *Anopheles stephensi* is the primary vector for **urban malaria**. It has uniquely adapted to city environments by breeding in artificial water containers such as overhead tanks, cisterns, fountain pools, and construction sites. Its ability to thrive in man-made containers allows it to maintain malaria transmission in densely populated urban centers. **2. Analysis of Incorrect Options:** * **Anopheles culicifacies:** This is the most important vector for **rural malaria** in India. It breeds in clean ground water like irrigation channels, pools, and borrow pits. It is responsible for nearly 60-70% of total malaria cases in the country. * **Anopheles sundaicus:** This species is restricted to **coastal areas**, particularly the Andaman and Nicobar Islands. It is known for breeding in brackish (salty) water. * **Anopheles fluviatilis:** This is a major vector in **hilly and forested areas** (especially in central and eastern India). It prefers breeding in slow-moving streams and is highly anthropophilic (prefers human blood). **High-Yield Clinical Pearls for NEET-PG:** * **Vector of Malaria in North-East India:** *Anopheles minimus* and *Anopheles dirus*. * **National Framework for Malaria Elimination (NFME):** India aims to eliminate malaria by **2030**. * **Urban Malaria Scheme (UMS):** Launched in 1971, it focuses on source reduction and anti-larval measures (like using *Gambusia* fish) specifically targeting *A. stephensi*. * **Bionomics:** Remember, *A. stephensi* is "Urban," while *A. culicifacies* is "Rural."

Non-Communicable Diseases Indian Medical PG Practice Questions and MCQs

Question 1: What is the post-exposure rabies vaccination schedule for a patient who has already been immunized?

A. 0, 3 (Correct Answer)
B. 0, 3, 14
C. 0, 7, 28
D. 8, 4, 0, 1, 1

Explanation: **Explanation:** The correct answer is **A (0, 3)**. This follows the WHO and National Guidelines for Rabies Prophylaxis regarding **re-exposure** in previously immunized individuals. **1. Why Option A is Correct:** When a person has documented evidence of a complete pre-exposure or post-exposure vaccination course (using modern Cell Culture Vaccines), they possess "immunological memory." Upon re-exposure, a rapid "booster" effect is required to elevate antibody titers. The recommended schedule is **two doses** of the vaccine, administered intramuscularly (or intradermally) on **Days 0 and 3**. Crucially, Rabies Immunoglobulin (RIG) is **not** required for these patients, even for Category III bites. **2. Why Other Options are Incorrect:** * **Option B (0, 3, 14):** This is not a standard recognized schedule for rabies. * **Option C (0, 7, 28):** This is the standard **Pre-exposure Prophylaxis (PrEP)** schedule for high-risk individuals (e.g., veterinarians, lab workers). * **Option D (8, 4, 0, 1, 1):** This refers to the **Thai Red Cross (Intradermal) Schedule** (2-2-2-0-2), but the numbers provided are jumbled and do not represent a standard post-exposure regimen. **High-Yield Clinical Pearls for NEET-PG:** * **Definition of "Previously Immunized":** A person who has received a full course of PEP or PrEP with Cell Culture Vaccine (CCV) or Purified Duck Embryo Vaccine (PDEV). * **RIG Rule:** RIG is contraindicated in previously immunized individuals as it may interfere with the secondary immune response. * **Standard PEP (Unvaccinated):** The Essen schedule (IM) is **0, 3, 7, 14, 28**. * **Site of Injection:** Always the **deltoid** in adults and the **anterolateral thigh** in children. **Never** in the gluteal region (due to lower neutralizing antibody titers).

Question 2: Which disease requires a vaccination certificate for international travel?

A. Cholera
B. Hepatitis
C. Yellow fever (Correct Answer)
D. Tetanus

Explanation: **Explanation:** The correct answer is **Yellow Fever**. Under the **International Health Regulations (IHR 2005)**, Yellow Fever is currently the only disease for which an International Certificate of Vaccination or Prophylaxis (ICVP) is legally required for travel between endemic and non-endemic zones. **Why Yellow Fever is correct:** Yellow Fever is a viral hemorrhagic fever transmitted by the *Aedes aegypti* mosquito. To prevent the "re-introduction" of the virus into countries where the vector is present but the disease is not (like India), travelers arriving from endemic zones (Sub-Saharan Africa and South America) must provide a valid vaccination certificate. The vaccine used is the **17D strain**, and the certificate becomes valid **10 days** after vaccination, lasting for the **lifetime** of the individual. **Why the other options are incorrect:** * **Cholera:** While previously required, the WHO removed Cholera from the list of mandatory vaccinations for international travel because the parenteral vaccine provides poor protection and does not prevent asymptomatic carriage. * **Hepatitis & Tetanus:** These are recommended vaccinations for personal protection based on the traveler's destination and risk profile, but they are not legally mandated by international law for border crossing. **High-Yield Clinical Pearls for NEET-PG:** * **Validity:** A Yellow Fever certificate is valid for life (as per 2016 WHO amendment). * **Quarantine:** If a traveler from an endemic zone lacks a valid certificate, they are kept in a mosquito-proof isolation ward for **6 days** (the incubation period of the disease). * **Polio:** Note that some countries (including India) may require Polio vaccination (OPV/IPV) for travelers coming from specific polio-endemic countries, but Yellow Fever remains the primary global requirement under IHR.

Question 3: All of the following are modes of transmission of leprosy except?

A. Breast milk
B. Blood transfusion (Correct Answer)
C. Transplacental spread
D. Droplet infection

Explanation: **Explanation:** Leprosy, caused by *Mycobacterium leprae*, is primarily a chronic infectious disease of the skin and peripheral nerves. Understanding its transmission is crucial for NEET-PG. **Why Blood Transfusion is the Correct Answer:** Unlike many other bacterial infections, **blood transfusion** is not a recognized mode of transmission for leprosy. *M. leprae* is an obligate intracellular pathogen that resides primarily within macrophages and Schwann cells. It does not survive well or circulate in the free plasma in concentrations sufficient to cause infection via transfusion. **Analysis of Incorrect Options:** * **Droplet Infection (Option D):** This is the **most common** and primary route of transmission. Bacilli are shed in large numbers from the nasal mucosa of untreated lepromatous patients and enter the susceptible host through the upper respiratory tract. * **Transplacental Spread (Option C):** Vertical transmission from an infected mother to the fetus across the placenta has been documented, though it is relatively rare. * **Breast Milk (Option A):** *M. leprae* has been detected in the breast milk of lactating mothers with lepromatous leprosy, making it a possible, albeit less common, route of transmission. **High-Yield Clinical Pearls for NEET-PG:** * **Incubation Period:** Average 3–5 years (the longest among bacterial infections). * **Portal of Entry:** Respiratory tract (most common) and broken skin. * **Infectivity:** Patients become non-infectious within days of starting Multidrug Therapy (MDT). * **Classification:** Ridley-Jopling (Immunological) vs. WHO (Operational: Paucibacillary vs. Multibacillary). * **First Sign:** Usually a pale (hypopigmented) or reddish patch on the skin with loss of sensation.

Question 4: Which indicator best represents the vector's burden in human malaria transmission?

A. Man biting rate (Correct Answer)
B. Inoculation rate
C. Slide positive rate
D. Human blood index

Explanation: ### Explanation **Correct Option: A. Man biting rate** The **Man Biting Rate (MBR)** is the most direct measure of the **vector's burden** in the transmission cycle. It is defined as the average number of bites received by a single person from a specific vector species per unit of time (usually per day). Since malaria transmission depends entirely on the frequency of contact between the mosquito and the human host, MBR is the primary indicator of the intensity of the vector's activity and the risk of exposure. **Analysis of Incorrect Options:** * **B. Inoculation Rate:** This measures the number of **infective** bites per person per unit of time. While it indicates transmission risk, it is a subset of the biting rate (only counting mosquitoes with sporozoites) and represents the "force of infection" rather than the overall vector burden. * **C. Slide Positive Rate (SPR):** This is a **parasitological indicator** derived from human surveillance (number of positive slides per 100 slides examined). It reflects the prevalence of the disease in the human population, not the vector's burden. * **D. Human Blood Index (HBI):** This measures the proportion of blood meals taken by a mosquito population from human hosts versus animals. It indicates the **host preference (anthropophily)** of the vector but does not quantify the frequency of biting or the total burden. **High-Yield Pearls for NEET-PG:** * **Annual Parasite Incidence (API):** The most sensitive index for measuring malaria burden in a community (used for planning under NCVBDC). * **Annual Blood Examination Rate (ABER):** Measures the efficiency of the surveillance system (Target: >10%). * **Entomological Inoculation Rate (EIR):** The best measure of the "force of infection" in an area (MBR × Sporozoite Rate). * **Infant Parasite Rate:** The best indicator of **recent/ongoing transmission** in a locality.

Question 5: What is the mechanism of action of cholera toxin?

A. Ganglioside GM1 receptor
B. Stimulation of adenyl cyclase activity
C. Both binding to the ganglioside GM1 receptor and stimulation of adenyl cyclase activity (Correct Answer)
D. Exotoxin action leading to disruption of cell function

Explanation: **Explanation:** The pathogenesis of Cholera is a classic example of an AB-type exotoxin mechanism. The correct answer is **C** because the process requires two distinct, sequential steps involving different subunits of the toxin. 1. **Binding (B-Subunit):** The B-subunit of the cholera toxin (choleragen) binds specifically to the **GM1 ganglioside receptors** located on the surface of the enterocytes in the small intestine. This acts as the "key" to enter the cell. 2. **Activation (A-Subunit):** Once inside, the A-subunit undergoes ADP-ribosylation of the Gs protein. This leads to the permanent **stimulation of adenyl cyclase activity**, causing a massive increase in intracellular **cAMP** levels. High cAMP inhibits sodium absorption and promotes active chloride secretion, leading to the characteristic "rice-water" diarrhea. **Analysis of Incorrect Options:** * **Option A & B:** These are partially correct but incomplete. The toxin cannot function without binding (A) and cannot cause disease without enzymatic activation (B). * **Option D:** While technically true that it is an exotoxin, this is a vague description. NEET-PG requires identifying the specific molecular pathway (GM1/cAMP) rather than a general classification. **High-Yield Clinical Pearls for NEET-PG:** * **The "Rice-Water" Stool:** Non-inflammatory, non-bloody, with a fishy odor. * **Electrolyte Profile:** Stool is high in Bicarbonate and Potassium (leading to metabolic acidosis and hypokalemia). * **Treatment Priority:** Rehydration is the cornerstone. **Oral Rehydration Salt (ORS)** is the most cost-effective intervention; **Doxycycline** is the drug of choice to reduce the duration of shedding. * **Gold Standard Diagnosis:** Stool culture on **TCBS (Thiosulfate Citrate Bile Salts Sucrose) agar**, where *V. cholerae* appears as yellow colonies.

Question 6: Under the National Programme for Control of Blindness, what is the target goal for the prevalence of blindness?

A. 0.10%
B. 0.31% (Correct Answer)
C. 0.50%
D. 1%

Explanation: The **National Programme for Control of Blindness and Visual Impairment (NPCBVI)**, launched in 1976, is a high-yield topic for NEET-PG. The primary objective of the programme is to reduce the prevalence of blindness through systematic intervention. ### **Explanation of the Correct Answer** **Option B (0.31%)** is correct. According to the **National Blindness and Visual Impairment Survey (2015-2019)**, the prevalence of blindness in India was found to be **0.36%**. Following these findings, the revised target goal under the NPCBVI was set to reduce the prevalence of blindness to **0.3% (specifically 0.31%) by the year 2020**. This target aligns with the global "VISION 2020: The Right to Sight" initiative. ### **Analysis of Incorrect Options** * **Option A (0.10%):** This is an over-ambitious figure and does not correspond to any current national or global target for total blindness prevalence. * **Option C (0.50%):** This was the previous target goal of the NPCB. However, once the prevalence dropped below this level (as per the 2015-19 survey), the target was further lowered to 0.31%. * **Option D (1%):** This represents the historical prevalence of blindness in India during the early phases of the programme (it was 1.1% in 2001-02). ### **High-Yield Clinical Pearls for NEET-PG** * **Definition of Blindness (NPCBVI):** Visual acuity < 3/60 in the better eye with best possible correction. * **Most Common Cause of Blindness in India:** Cataract (approx. 66.2%). * **Most Common Cause of Visual Impairment:** Uncorrected Refractive Errors. * **Target Population:** The programme focuses heavily on the 50+ age group, where the prevalence is significantly higher (approx. 1.99%). * **WHO Definition Change:** Note that the NPCBVI definition of blindness was recently updated to align with the WHO definition (changing from < 6/60 to < 3/60) to ensure uniform global reporting.

Question 7: Which of the following is most strongly associated with coronary heart disease?

A. Apolipoproteins (Correct Answer)
B. VLDL
C. HDL
D. Total lipoproteins

Explanation: **Explanation:** The correct answer is **Apolipoproteins**. In modern cardiovascular epidemiology, apolipoproteins (specifically the **ApoB/ApoA1 ratio**) are considered the most accurate and strongest predictors of coronary heart disease (CHD) risk, even superior to traditional lipid profiles. 1. **Why Apolipoproteins are correct:** Apolipoproteins are the protein components of lipoproteins. **ApoB** is found on all atherogenic particles (LDL, VLDL, IDL), representing the total number of potentially harmful particles. **ApoA1** is the primary protein of HDL (cardioprotective). The INTERHEART study established that the ApoB/ApoA1 ratio is a more powerful predictor of myocardial infarction than any other lipid parameter because it reflects the balance between cholesterol transport into the arterial wall versus its removal. 2. **Why other options are incorrect:** * **VLDL:** While VLDL contributes to triglyceride transport, it is a less specific predictor of CHD compared to the total atherogenic burden measured by ApoB. * **HDL:** Often called "good cholesterol," a low HDL is a risk factor, but it is a less potent predictor of clinical events than the ratio of atherogenic to anti-atherogenic particles. * **Total Lipoproteins:** This is a broad category. Total cholesterol levels can be misleading if a patient has high HDL, making it a weaker predictor than specific apolipoprotein markers. **High-Yield Clinical Pearls for NEET-PG:** * **INTERHEART Study:** Identified the ApoB/ApoA1 ratio as the single most important risk factor for MI globally. * **Rule of Thumb:** High ApoB = High Risk; High ApoA1 = Low Risk. * **Metabolic Syndrome:** Characterized by high triglycerides and low HDL, but even here, ApoB remains a more stable marker as it is not affected by fasting status.

Question 8: In sickle cell trait patients, there is a reduced risk of which of the following diseases?

A. Typhoid
B. Malaria (Correct Answer)
C. G-6PD deficiency
D. Filaria

Explanation: **Explanation:** The correct answer is **Malaria**. This phenomenon is a classic example of **Heterozygote Advantage** (or Balanced Polymorphism), where the sickle cell trait (HbAS) provides a survival advantage against severe malaria, specifically *Plasmodium falciparum*. **Why Malaria is the correct answer:** Individuals with sickle cell trait have red blood cells (RBCs) that tend to sickle when infected by the parasite. These damaged RBCs are prematurely cleared by the spleen, reducing the overall parasite load. Furthermore, the sickling process disrupts the parasite's ability to digest hemoglobin and impairs the expression of adhesion proteins (like PfEMP-1) on the RBC surface, preventing the sequestration of infected cells in vital organs. This significantly reduces the risk of severe complications like cerebral malaria. **Analysis of Incorrect Options:** * **A. Typhoid:** Caused by *Salmonella typhi*, this is a bacterial infection of the gastrointestinal tract and bloodstream. Hemoglobinopathies do not provide protective immunity against it. * **C. G-6PD deficiency:** This is a separate genetic enzymopathy. While both G-6PD deficiency and Sickle Cell Trait are prevalent in malaria-endemic regions due to similar evolutionary pressures, one does not reduce the risk of the other. * **D. Filaria:** This is a helminthic infection involving the lymphatic system. Its pathogenesis is unrelated to hemoglobin structure or RBC survival. **High-Yield Clinical Pearls for NEET-PG:** * **Balanced Polymorphism:** This term describes how a potentially harmful allele (HbS) is maintained in a population because the heterozygote state (HbAS) offers a survival benefit. * **Other Protective Traits:** Besides Sickle Cell Trait, **G-6PD deficiency**, **Thalassemia**, and **Duffy Antigen negativity** (protective against *P. vivax*) are also associated with malaria resistance. * **Diagnosis:** On Hb electrophoresis, Sickle Cell Trait shows **HbA > HbS**.

Question 9: Which species of Anopheles mosquito is responsible for urban malaria?

A. Anopheles culicifacies
B. Anopheles stephensi (Correct Answer)
C. Anopheles sundaicus
D. Anopheles fluviatilis

Explanation: **Explanation:** The correct answer is **Anopheles stephensi**. In India, malaria transmission is highly dependent on the specific ecological niches of various *Anopheles* species. **1. Why Anopheles stephensi is correct:** *Anopheles stephensi* is the primary vector for **urban malaria**. It has uniquely adapted to city environments by breeding in artificial water containers such as overhead tanks, cisterns, fountain pools, and construction sites. Its ability to thrive in man-made containers allows it to maintain malaria transmission in densely populated urban centers. **2. Analysis of Incorrect Options:** * **Anopheles culicifacies:** This is the most important vector for **rural malaria** in India. It breeds in clean ground water like irrigation channels, pools, and borrow pits. It is responsible for nearly 60-70% of total malaria cases in the country. * **Anopheles sundaicus:** This species is restricted to **coastal areas**, particularly the Andaman and Nicobar Islands. It is known for breeding in brackish (salty) water. * **Anopheles fluviatilis:** This is a major vector in **hilly and forested areas** (especially in central and eastern India). It prefers breeding in slow-moving streams and is highly anthropophilic (prefers human blood). **High-Yield Clinical Pearls for NEET-PG:** * **Vector of Malaria in North-East India:** *Anopheles minimus* and *Anopheles dirus*. * **National Framework for Malaria Elimination (NFME):** India aims to eliminate malaria by **2030**. * **Urban Malaria Scheme (UMS):** Launched in 1971, it focuses on source reduction and anti-larval measures (like using *Gambusia* fish) specifically targeting *A. stephensi*. * **Bionomics:** Remember, *A. stephensi* is "Urban," while *A. culicifacies* is "Rural."

Question 10: Which of the following describes a carrier who received the source of infection from other carriers?

A. Incubatory carrier (Correct Answer)
B. Convalescent carrier
C. Healthy carrier
D. Chronic carrier

Explanation: ### Explanation The correct answer is **Incubatory carrier**. In epidemiology, a **carrier** is an infected person who harbors a specific infectious agent without having clinical disease and serves as a potential source of infection for others. **1. Why Incubatory Carrier is correct:** An **incubatory carrier** is an individual who is in the incubation period of a disease (the time between exposure and the onset of symptoms) but is already shedding the infectious agent. In the context of transmission cycles, an incubatory carrier often acquires the infection from another carrier (who may be healthy, chronic, or also incubatory) or a subclinical case, rather than a symptomatic patient. This "carrier-to-carrier" transmission is a hallmark of diseases like Hepatitis B, HIV, and Diphtheria. **2. Analysis of Incorrect Options:** * **Convalescent carrier:** These are individuals who continue to shed the infectious agent during the period of recovery (convalescence) after the clinical symptoms have disappeared (e.g., Typhoid, Cholera). * **Healthy carrier:** These individuals harbor the pathogen but never develop clinical illness (subclinical infection). They are often the most dangerous because they are undetected (e.g., Poliomyelitis, Meningococcal meningitis). * **Chronic carrier:** An individual who continues to harbor the infectious agent for an indefinite period (usually >6 months or a year) following the initial infection (e.g., Typhoid Mary). **High-Yield Clinical Pearls for NEET-PG:** * **Typhoid:** Can produce all types of carriers (Incubatory, Convalescent, and Chronic). * **Diphtheria:** Known for producing both incubatory and healthy carriers. * **Epidemiological Importance:** Carriers are often more dangerous than "cases" because their mobility is unrestricted, and they remain hidden in the community (the "Iceberg Phenomenon"). * **Chronic Carrier Definition:** In Typhoid, a chronic carrier is defined as someone shedding *S. typhi* in stools for more than **one year**.

Practice by Chapter

Epidemiology of NCDs

Practice Questions

Cardiovascular Disease Prevention

Practice Questions

Diabetes Control Program

Practice Questions

Cancer Screening and Control

Practice Questions

Chronic Respiratory Diseases

Practice Questions

Mental Health Program

Practice Questions

Blindness Control Program

Practice Questions

Accident and Injury Prevention

Practice Questions

NCD Risk Factor Surveillance

Practice Questions

National Program for Prevention and Control of Cancer, Diabetes, CVD, and Stroke

Practice Questions

Oral Health Program

Practice Questions

Geriatric Health Issues

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free